Sanofi says U.S. probing Plavix disclosures to FDA

PARIS Fri Mar 8, 2013 1:12pm EST

Bottles of Plavix shown on display at a pharmacy in North Aurora, Illinois July 24, 2008. REUTERS/Jeff Haynes

Bottles of Plavix shown on display at a pharmacy in North Aurora, Illinois July 24, 2008.

Credit: Reuters/Jeff Haynes

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

PARIS (Reuters) - The U.S. Department of Justice (DoJ) is investigating disclosures to the Food & Drug Administration (FDA) about the variable response that certain patients may have to blood-thinner Plavix, Sanofi said in its annual report.

The French drugmaker said it had became aware of the probe in June 2012 and was cooperating with the DoJ.

Plavix, once the world's second-best selling drug, was co-marketed by Sanofi and U.S. drugmaker Bristol-Myers Squibb before it lost patent protection in May 2012.

The U.S. FDA added a so-called boxed warning to Plavix in 2010 to highlight that the drug could be less effective in certain patients who could not metabolize it properly.

A Sanofi spokeswoman declined to elaborate on the statement in the annual report.

The DoJ and Bristol Myers Squibb were not immediately available for comment.

(Reporting by Elena Berton, Toni Clarke and Ransdell Pierson; Editing by David Holmes)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
Of course it doesn’t work anymore now that they have a new one.

Mar 11, 2013 10:15pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.